Determination of the target population in early benefit assessments in Germany: challenges for non-small-cell lung cancer

C. Thoren (), C. Balg, J. Gibbert, S. Mostardt, M. Ripoll, D. Schierbaum, S. Schiller and A. Schwalm
Additional contact information
C. Thoren: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
C. Balg: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
J. Gibbert: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
S. Mostardt: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
M. Ripoll: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
D. Schierbaum: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
S. Schiller: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
A. Schwalm: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

The European Journal of Health Economics, 2020, vol. 21, issue 6, No 6, 893 pages

Abstract: Abstract Objectives Dossiers submitted for early benefit assessments in Germany also provide information on the precise determination of the target population (patients eligible for a drug). The situation is complex for non-small-cell lung cancer (NSCLC) due to highly specific therapeutic indications. Our aim was to compare the different methodological steps applied to determine the target population in dossiers on drugs for NSCLC. Methods We analysed NSCLC dossiers assessed by the German Institute for Quality and Efficiency in Health Care (IQWiG) between 01.01.2011 and 31.12.2017. Methodological details regarding the determination of the target population were extracted and compared. Results We analysed 23 NSCLC dossiers. In all dossiers, the target population was determined using the number of all patients with lung cancer as the basis for calculations. This patient population was further reduced in several successive steps by assuming proportions of patients with a specific characteristic (e.g. disease stage). The most important calculation steps were patients with NSCLC (n = 23 dossiers), with a specific disease stage (n = 23), with a specific tumour mutation (n = 14), with a specific tumour histology (n = 7), without prior treatment (n = 15), with pretreatment in second or further treatment lines (n = 17), and/or with specific pretreatments (n = 9). The proportions of patients determined within the same calculation step varied considerably between dossiers. Discussion The calculation methods applied and the target population sizes reported in NSCLC dossiers vary considerably. A consensus with regard to the databases and calculation methods used to determine the target population in NSCLC would be helpful to reduce variations.

Keywords: Non-small-cell lung cancer; NSCLC; Early benefit assessment; New drugs; Target population; I10 (General); I18 (Government Policy-Regulation-Public Health) (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-020-01180-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:21:y:2020:i:6:d:10.1007_s10198-020-01180-1

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-020-01180-1

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().